bio sketch column
Professor Paul Workman is Chief Executive and President of The Institute of Cancer Research (ICR), and Harrap Professor of Pharmacology and Therapeutics. Paul has been responsible for more than 20 molecularly targeted cancer drugs entering clinical trial. He is especially renowned for his research in the discovery, chemical biology and molecular pharmacology of drugs and chemical probes acting on protein kinases, PI3 kinases and the molecular chaperone HSP90. Prior to joining ICR in 1997, Paul spent 4 years leading cancer research at AstraZeneca; he was a scientific founder of Piramed Pharma (acquired by Roche) and Chroma Therapeutics. Paul has received several awards including the American Association of Cancer Research Team Science Award; the Cancer Research UK Translational Cancer Research Prize; the George and Christine Sosnovsky Award and World Entrepreneur Award, both of the Royal Society of Chemistry; and the international Raymond Bourgine Award for excellence in cancer research. In 2016 Paul was elected a Fellow of the Royal Society, the UK’s national academy of science.